ATIM-28. PHASE 2 STUDY OF ERC1671 PLUS BEVACIZUMAB VS...

Neuro-Oncology 2018 / 11 Vol. 20; Iss. suppl_6

ATIM-28. PHASE 2 STUDY OF ERC1671 PLUS BEVACIZUMAB VS BEVACIZUMAB PLUS PLACEBO IN RECURRENT GBM INTERIM RESULTS AND CORRELATIONS WITH CD4+ T LYMPHOCYTE COUNTS

Bota, Daniela A, Chung, Jinah, Dandekar, Manisha, Carrillo, Jose A, Kong, Xiao-tang, Beverly Fu, Dan, Hsu, Frank P K, Schönthal, Alex H, Hofman, Florence M, Chen, Thomas C, Zidovetzki, Raphael, Pretto
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
20
Language:
english
Journal:
Neuro-Oncology
DOI:
10.1093/neuonc/noy148.023
Date:
November, 2018
File:
PDF, 85 KB
english, 2018
Conversion to is in progress
Conversion to is failed